March 09, 2023, Toronto – This week, Geneseeq Technology Inc. has announced the initiation of the MOTION study in collaboration with ten clinical sites to evaluate the performance of Geneseeq’s minimal residual disease test SHIELDING™ in patients with operable early-stage non-small cell lung cancer (NSCLC).
This prospective study aims to enroll 405 surgical stage IA-IB NSCLC patients that will be randomized into standard-of-care subgroup and MRD-interfered subgroup with a follow-up period of three years. MRD status is determined by SHIELDING™ using the plasma samples collected after resection. In the standard-of-care subgroup, patients will receive standard-of-care treatment and follow-up MRD detection every six months. In the MRD-interfered subgroup, the patients are further stratified by MRD status. The MRD-positive patients will receive adjuvant therapy and follow-up MRD detection every three months while the MRD-negative patients will undergo observation and follow-up MRD detection every six months. The primary endpoint is to compare disease-free survival (DFS) between the standard-of-care subgroup and MRD-interfered subgroup, as well as DFS between MRD-positive and MRD-negative patients.
SHIELDING™, launched in early 2021, is Geneseeq’s first commercially available MRD product in China for clinical use in the management of early and mid-stage solid tumors. Thus far, Geneseeq has released the results of multiple studies evaluating the performance of SHIELDING™ in different early-stage solid tumors, demonstrating the substantial clinical value of MRD assessment.
“The initiation of the MOTION study further expands the evidence on clinical values of SHIELDING™ in real-world settings. We’re confident that the use of SHIELDING™ will benefit patients with improved disease outcomes”, says Dr. Xue Wu, the CEO of Geneseeq Technology Inc.